Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can switching cancer therapy early extend life in stomach cancer?

NCT ID NCT07763171

Not yet recruiting Disease control Sponsor: Gruppo Oncologico del Nord-Ovest Source: ClinicalTrials.gov ↗

First seen Aug 13, 2026 · Last updated Aug 14, 2026 · Updated 1 time

Summary

This trial is testing whether switching to a different drug combination after initial chemotherapy can help people with advanced gastroesophageal cancer live longer without the disease worsening. Participants first receive standard chemotherapy plus an immunotherapy drug (tislelizumab). Those whose cancer does not progress are then randomly assigned to either continue the same chemotherapy plus tislelizumab or switch to a maintenance regimen of paclitaxel, ramucirumab, and tislelizumab. The goal is to see if the switch improves progression-free survival compared to continuing the original treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
A combination of paclitaxel, ramucirumab, and tislelizumab as switch maintenance therapy
What this could lead to
If successful, this approach could offer a new standard of care for advanced gastroesophageal cancer, potentially extending the time before the disease worsens and improving quality of life.
What could go wrong
This is a phase III trial, but results are not yet available. The switch maintenance may not improve outcomes compared to continuing chemotherapy, and the combination may cause more side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GASTROESOPHAGEAL ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gastroesophageal adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GASTROESOPHAGEAL ADENOCARCINOMA

Contacts and locations

Locations

  • ASST Grande Ospedale Metropolitano Niguarda

    Milan, Italy

  • ASST Ospedale Maggiore di Crema

    Crema, Italy

  • ASST di Cremona

    Cremona, Italy

  • Azienda Ospedaliera Universitaria "Luigi Vanvitelli"

    Naples, Italy

  • Azienda Ospedaliera Universitaria San Luigi Gonzaga

    Orbassano, Torino, Italy

  • Azienda Ospedaliera Universitaria di Modena

    Modena, Italy

  • Azienda Ospedaliero-Universitaria Maggiore della Carità

    Novara, Italy

  • Azienda USL della Romagna

    Ravenna, Italy

  • Centro Riferimento Oncologico

    Aviano, Italy

  • Fondazione IRCCS Istituto Nazionale dei Tumori di Milano

    Milan, Italy

  • IRCCS Azienda ospedaliero-universitaria di Bologna - Policlinico Sant'Orsola

    Bologna, Italy

  • IRCCS Istituto Tumori Giovanni Paolo II

    Bari, Italy

  • IRCCS Ospedale Policlinico San Martino

    Genova, Italy

  • Istituto Nazionale Tumori IRCCS Fondazione G. Pascale

    Naples, Italy

  • Istituto Oncologico Veneto I.R.C.C.S

    Padova, Italy

  • Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST IRCCS

    Meldola, Italy

  • Presidio Ospedaliero Ospedale del Mare

    Naples, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.